开源证券近日发布欧洲电动车销量月报：11月欧洲9国新能源车维持高增长，其中法国、意大利补贴落 地后BEV高速增长，挪威年底迎来电车抢装。2025年11月欧洲9国新能源车销量28.1万辆，同比 +38.6%，新能源渗透率34.3%，同比+9.0pcts。其中，BEV销量19.0万辆，同比+40.5%；PHEV销量9.1万 辆，同比+35.0%。 投资建议 以下为研究报告摘要： 欧盟委员会提案调整了2035年减排目标，但我们预计此次提案并不会影响欧洲电动化的长期趋势，相 反，提案将对小型电动汽车给予"超级积分"，并对企业用车的零排放车型占比加以约束，来进一步促进 欧洲电动车的销量。此外，2025年底至2026H1，各车企新一代纯电车型将陆续推向市场，新车型有望 带动欧洲电车市场放量。投资建议：（1）锂电池：推荐宁德时代、亿纬锂能、欣旺达；受益标的中创 新航、国轩高科；（2）锂电材料：推荐湖南裕能、天赐材料；受益标的富临精工、万润新能；容百科 技、当升科技、中伟股份、厦钨新能、华友钴业；星源材质、恩捷股份；新宙邦；天奈科技；（3）锂 电结构件：推荐铭利达、敏实集团；受益标的科达利、和胜股份；（4）电源/电驱系统：推 ...

Investment Rating - The report provides a positive investment rating for the industry, indicating a growth potential in the upcoming years [5][10][22]. Core Insights - The industry is projected to experience significant growth, with a compound annual growth rate (CAGR) of approximately 10.5% from 2021 to 2025 [8][18]. - The market for electric vehicles (EVs) is expected to expand, with battery electric vehicles (BEVs) showing a notable increase in sales, projected to reach 80.2 million units by 2025 [10][11]. - The report highlights a shift towards hybrid and electric vehicles, with plug-in hybrid electric vehicles (PHEVs) and extended-range electric vehicles (EREVs) also gaining traction [10][11]. Summary by Sections Market Overview - The total market size for the industry is expected to reach approximately $1,814 billion by 2025, with a growth rate of 12.4% [5][6]. - The market for SUVs and MPVs is projected to grow significantly, with SUVs expected to dominate the market share [5][6]. Sales Projections - Sales of BEVs are anticipated to grow by 35.9% year-on-year, reaching 80.2 million units by 2025 [10][11]. - The report indicates that the sales of EREVs will also see a substantial increase, with a projected growth of 21.0% [10][11]. Regional Insights - The Asia-Pacific region is expected to lead the market, accounting for over 50% of the total sales by 2025 [10][11]. - North America and Europe are also projected to show significant growth, driven by increasing consumer demand for electric vehicles [10][11]. Competitive Landscape - The report identifies key players in the industry, highlighting their market shares and growth strategies [10][11]. - It emphasizes the importance of innovation and technology in maintaining competitive advantages within the market [10][11].

Group 1: Electric Power Equipment and New Energy - In Q1 2025, European BEV sales from companies like Renault, Volkswagen, and BMW saw significant growth, with Renault's BEV sales up by 88%, Volkswagen's by 113%, and BMW's by 64% [5][6] - Chinese automakers are increasing exports to Europe, with BYD's sales reaching 14,000 units, a 124% year-on-year increase, while MG's sales dropped by 47% [6] - European automakers are set to launch new electric vehicle models from 2025 to 2026, which is expected to solidify the trend towards electrification [7] - The pressure from carbon emission assessments is high, but the introduction of new models is anticipated to help exceed targets by 2027 [8] Group 2: Social Services - Recent research highlights hyaluronic acid (HA) as a key factor in the aging process, marking a shift towards systemic interventions in anti-aging strategies [10][11] - Huaxi Biological Technology has positioned itself at the forefront of ECM research, with two new anti-aging products recently approved, indicating a shift from local to systemic interventions in anti-aging [12][13] Group 3: Media - Bilibili reported a revenue of 7.003 billion yuan in Q1 2025, a 23.6% year-on-year increase, with a net profit of 362 million yuan, indicating a turnaround from losses [15][16] - The platform's DAU reached 107 million, a 4.5% increase year-on-year, with MAU hitting a record high of 368 million, suggesting strong user growth [17][19] - The company is expected to benefit from the growth in gaming, membership, advertising, and IP monetization, driving future revenue growth [15][19] Group 4: Pharmaceuticals - The company has increased its stake in AR882 to 100%, enhancing its market position for this gout treatment, which shows significant potential for growth [21][22] - AR882 has demonstrated superior efficacy and safety in clinical trials, positioning it as a best-in-class product in the market [22][23] - The company is increasing its R&D investment, with a pipeline of 15 innovative drugs showing promising early-stage results [23]